These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37651295)

  • 1. Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes.
    Med Lett Drugs Ther; 2023 Aug; 65(1683):130-132. PubMed ID: 37651295
    [No Abstract]   [Full Text] [Related]  

  • 2. Sotagliflozin (Inpefa) for heart failure.
    Med Lett Drugs Ther; 2023 Jul; 65(1681):114-116. PubMed ID: 37460142
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison chart: SGLT2 inhibitors.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):e2-e4. PubMed ID: 33429417
    [No Abstract]   [Full Text] [Related]  

  • 4. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2022 Nov; 64(1663):177-184. PubMed ID: 36384763
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
    [No Abstract]   [Full Text] [Related]  

  • 6. In brief: Empagliflozin (Jardiance) for chronic kidney disease.
    Med Lett Drugs Ther; 2023 Nov; 65(1689):183-184. PubMed ID: 37935020
    [No Abstract]   [Full Text] [Related]  

  • 7. Ertugliflozin for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):70-72. PubMed ID: 29667948
    [No Abstract]   [Full Text] [Related]  

  • 8. In brief: Expanded heart failure indication for empagliflozin (Jardiance).
    Med Lett Drugs Ther; 2022 Apr; 64(1648):57. PubMed ID: 35436772
    [No Abstract]   [Full Text] [Related]  

  • 9. Empagliflozin (Jardiance) for heart failure with reduced ejection fraction.
    Med Lett Drugs Ther; 2021 Nov; 63(1636):171-172. PubMed ID: 35085205
    [No Abstract]   [Full Text] [Related]  

  • 10. In brief: Expanded heart failure indication for dapagliflozin (Farxiga).
    Med Lett Drugs Ther; 2023 Jun; 65(1679):101-102. PubMed ID: 37339090
    [No Abstract]   [Full Text] [Related]  

  • 11. Empagliflozin (Jardiance) for heart failure.
    Med Lett Drugs Ther; 2020 Nov; 62(1611):177-178. PubMed ID: 33438858
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 13. In brief: Canagliflozin and lower limb amputations.
    Med Lett Drugs Ther; 2020 Sep; 62(1607):152. PubMed ID: 32960870
    [No Abstract]   [Full Text] [Related]  

  • 14. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
    Johnston R; Uthman O; Cummins E; Clar C; Royle P; Colquitt J; Tan BK; Clegg A; Shantikumar S; Court R; O'Hare JP; McGrane D; Holt T; Waugh N
    Health Technol Assess; 2017 Jan; 21(2):1-218. PubMed ID: 28105986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
    Allegretti AS; Zhang W; Zhou W; Thurber TK; Rigby SP; Bowman-Stroud C; Trescoli C; Serusclat P; Freeman MW; Halvorsen YC
    Am J Kidney Dis; 2019 Sep; 74(3):328-337. PubMed ID: 31101403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value.
    Xie Y; Wei Y; Li D; Pu J; Ding H; Zhang X
    J Cardiovasc Pharmacol; 2023 Jan; 81(1):4-14. PubMed ID: 36607775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of the Safety and Efficacy of Bexagliflozin for the Management of Type 2 Diabetes.
    Cowart K; Coon S; Carris NW
    Ann Pharmacother; 2024 May; 58(5):514-522. PubMed ID: 37568270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.